Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous adipose-derived stem cells + fibrin glue
- Development stage
- Unknown
- Lead developer
- Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intralesional
01
Overview
This investigational autologous cell therapy consists of expanded adipose-derived mesenchymal stem cells (ASCs) combined with fibrin glue. Developed by the Health Research Institute Fundación Jiménez Díaz (FIIS-FJD), it is specifically designed for the treatment of complex cryptoglandular perianal fistulas in patients without inflammatory bowel disease (non-IBD). The treatment involves harvesting the patient's own adipose tissue, expanding the mesenchymal stem cells in vitro using human platelet lysate, and then injecting 100 million expanded cells into the fistula tract along with fibrin glue. The fibrin glue acts as a biological scaffold and sealant, while the ASCs provide immunomodulatory and pro-regenerative signals to promote tissue healing and re-epithelialization of the fistula tract. Long-term follow-up from the Phase 3 FISPAC trial demonstrated significantly higher healing rates compared to fibrin glue alone.
- Other names
- autologous expanded adipose-derived stem cellsexpanded ASCsFIIS-FJD ASC therapyautologous ASCs + fibrin glue
Beyond the preview
Go deeper on autologous adipose-derived stem cells + fibrin glue.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous adipose-derived stem cells + fibrin glue.